Chloroquine With Taxane Chemotherapy for Advanced or Metastatic Breast Cancer After Anthracycline Failure (CAT)

Model scores of the 29,894 trials active now.

Model score 41% for any early termination, 18% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 26% of the time (3,728 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2019-03-01. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: breast cancertumorsulnheartqt
  Phrases that lowered it: safety ofand safetyefficacy andthe efficacythe study
• Sponsor's past termination rate: 57.1% (raises risk) · Sponsor's track record
• Phase: 2 (raises risk) · Design
• Accepts healthy volunteers: No (raises risk) · Who can join
• Disease area, cancer: Yes (raises risk) · Disease area
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Design: single group (raises risk) · Design
• Primary purpose: treatment (raises risk) · Design
• Drug's FAERS reports marked serious: 95.7% (raises risk) · Drug's FDA history
• Disease area, dermatology: Yes (raises risk) · Disease area
• Drug's FAERS reports with a death: 19.3% (lowers risk) · Drug's FDA history
• Minimum age: 18 (raises risk) · Who can join
• Keywords listed: 18 (raises risk) · Design
• Maximum age: not given (raises risk) · Who can join
• Trials the sponsor started in the prior 2 years: 1 (raises risk) · Sponsor's track record
• Blinding: none (raises risk) · Design
• Number of arms: 1 (raises risk) · Design
• Sponsor's past trials: 14 (raises risk) · Sponsor's track record
• Drugs with FDA adverse-event history: 3 (lowers risk) · Drug's FDA history
• Collaborators: 0 (raises risk) · Design

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Neoadjuvant Sunitinib With Paclitaxel/Carboplatin in Patients With Triple-Negative Breast Cancer NCT00887575 · started 2009 · scored riskier than 92% of active trials completed
• Ixabepilone and Cyclophosphamide as Neoadjuvant Therapy in HER-2 Negative Breast Cancer NCT00866905 · started 2009 · scored riskier than 80% of active trials completed
• Neoadjuvant Ixabepilone/Carboplatin/Trastuzumab in HER2-Positive Locally Advanced Breast Cancer NCT00821886 · started 2009 · scored riskier than 90% of active trials completed
• A Randomized Trial of Ixempra Versus Taxol in Adjuvant Therapy of Triple Negative Breast Cancer NCT00789581 · started 2008 · scored riskier than 60% of active trials completed
• Plinabulin iv Solution in Prevention of TAC Induced Neutropenia NCT04227990 · started 2017 · scored riskier than 79% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.